
Burning Rock Biotech Limited BNR
$ 20.37
-3.96%
Annual report 2021
added 12-23-2023
Burning Rock Biotech Limited Total Assets 2011-2025 | BNR
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Burning Rock Biotech Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.28 B | 2.66 B | 848 M | 373 M | - | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.66 B | 373 M | 1.54 B |
Quarterly Total Assets Burning Rock Biotech Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 2.28 B | - | - | - | 2.66 B | - | - | - | 848 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.66 B | 848 M | 1.93 B |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M | ||
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Co-Diagnostics
CODX
|
95.3 M | $ 0.23 | -4.49 % | $ 6.75 M | ||
|
Castle Biosciences
CSTL
|
531 M | $ 39.43 | -1.65 % | $ 1.1 B | ||
|
DarioHealth Corp.
DRIO
|
96.4 M | $ 10.15 | 1.1 % | $ 288 M | ||
|
Brainsway Ltd.
BWAY
|
94.3 M | $ 19.45 | 0.83 % | $ 99.4 M | ||
|
DexCom
DXCM
|
6.26 B | $ 67.27 | -0.22 % | $ 26 B | ||
|
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | ||
|
BioNano Genomics
BNGO
|
76.7 M | $ 1.5 | -1.32 % | $ 1.91 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M | ||
|
Danaher Corporation
DHR
|
77.5 B | $ 230.14 | -0.39 % | $ 168 B | ||
|
Exact Sciences Corporation
EXAS
|
5.93 B | $ 101.64 | 0.1 % | $ 18.8 B | ||
|
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | ||
|
Fulgent Genetics
FLGT
|
1.22 B | $ 26.69 | -1.2 % | $ 807 M | ||
|
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | ||
|
Myriad Genetics
MYGN
|
1.03 B | $ 6.44 | -1.68 % | $ 583 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | ||
|
ENDRA Life Sciences
NDRA
|
4.45 M | $ 4.93 | -3.33 % | $ 2.65 M | ||
|
Neogen Corporation
NEOG
|
3.44 B | $ 7.09 | -0.77 % | $ 1.54 B | ||
|
CareDx, Inc
CDNA
|
467 M | $ 19.42 | -1.6 % | $ 1.04 B | ||
|
National Research Corporation
NRC
|
122 M | $ 18.55 | -0.54 % | $ 455 M | ||
|
Celcuity
CELC
|
245 M | $ 101.99 | -0.6 % | $ 4.02 B | ||
|
Anixa Biosciences
ANIX
|
21.6 M | $ 3.23 | -5.56 % | $ 103 K | ||
|
Pacific Biosciences of California
PACB
|
1.75 B | $ 1.79 | -4.79 % | $ 454 M | ||
|
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | ||
|
IQVIA Holdings
IQV
|
26.9 B | $ 226.18 | 0.07 % | $ 41 B | ||
|
Koninklijke Philips N.V.
PHG
|
29 B | $ 26.96 | -0.07 % | $ 20 B | ||
|
Precipio
PRPO
|
18.1 M | $ 24.6 | 2.99 % | $ 31.9 M | ||
|
Guardant Health
GH
|
1.49 B | $ 104.09 | 1.67 % | $ 12.8 B | ||
|
Quidel Corporation
QDEL
|
1.87 B | $ 28.68 | -0.8 % | $ 1.21 B | ||
|
QIAGEN N.V.
QGEN
|
5.69 B | $ 45.46 | -0.14 % | $ 10.1 B | ||
|
Aspira Women's Health
AWH
|
17.4 M | - | -6.19 % | $ 10.5 M | ||
|
Sotera Health Company
SHC
|
3.07 B | $ 17.65 | -0.28 % | $ 4.99 B | ||
|
Illumina
ILMN
|
6.3 B | $ 134.92 | -0.29 % | $ 21.5 B | ||
|
Charles River Laboratories International
CRL
|
7.53 B | $ 203.17 | -0.35 % | $ 10.4 B | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 176.14 | 0.14 % | $ 19.6 B | ||
|
Biodesix
BDSX
|
97.2 M | $ 6.76 | -0.9 % | $ 877 M | ||
|
Trinity Biotech plc
TRIB
|
103 M | $ 1.03 | 1.02 % | $ 61.9 M | ||
|
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | ||
|
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 253.45 | -0.4 % | $ 21.3 B | ||
|
ICON Public Limited Company
ICLR
|
16.9 B | $ 181.52 | -1.18 % | $ 15 B | ||
|
IDEXX Laboratories
IDXX
|
3.29 B | $ 687.17 | -0.15 % | $ 56.7 B |